Alector (ALEC) Stock Price, News & Analysis

Company Overview

Alector, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing immuno-neurology therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform focuses on harnessing the innate immune system to address the underlying causes of disorders such as Alzheimer’s disease, frontotemporal dementia (FTD), and progressive multiple sclerosis (MS). By targeting key immune pathways in the brain, Alector aims to modulate microglial and macrophage function to clear toxic proteins and restore neuronal health.

The company’s pipeline features several lead programs, including AL001, an antibody designed to correct progranulin deficiencies in patients with FTD, and AL002, which targets the TREM2 receptor to enhance microglial response. Additional candidates address protein aggregation and inflammatory processes, positioning Alector at the forefront of immune-based approaches to neurodegeneration. Each program is progressing through clinical or preclinical development, with an emphasis on robust biomarker strategies to demonstrate mechanism of action and disease modification.

Founded in 2013 by Dr. Arnon Rosenthal and a team of immunologists and neuroscientists, Alector has built collaborative relationships with academic institutions and strategic partners to accelerate its research efforts. The company completed its initial public offering in 2018 and has since advanced multiple clinical trials across North America and Europe. Partnerships with leading pharmaceutical firms and research consortia have expanded access to novel targets and bolstered translational capabilities.

Headquartered in South San Francisco, with research operations in Cambridge, U.K., Alector benefits from proximity to major biotech hubs. Under the leadership of Dr. Arnon Rosenthal as President and CEO, alongside a seasoned executive team with deep experience in drug development, the company continues to build on its mission to translate cutting-edge science into therapies that address the unmet needs of patients suffering from debilitating neurodegenerative conditions.

Key Stats

• Today's Range: $1.58 to $1.70
• 50-Day Range: $1.07 to $1.72
• 52-Week Range: $0.87 to $6.78
• Volume: 299,435 shs
• Average Volume: 827,427 shs
• Market Capitalization: $158.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Alector Stock Analysis - MarketRank™

Alector scored higher than 78% of companies evaluated by MarketBeat, and ranked 240th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Alector has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Alector has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alector are expected to decrease in the coming year, from ($1.88) to ($1.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alector is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alector is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alector has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.22% of the float of Alector has been sold short.

Short Interest Ratio / Days to Cover

Alector has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Alector has recently decreased by 2.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alector does not currently pay a dividend.

Dividend Growth

Alector does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.92

Percentage of Shares Shorted

8.22% of the float of Alector has been sold short.

Short Interest Ratio / Days to Cover

Alector has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Alector has recently decreased by 2.98%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Alector has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

Search Interest

1 people have searched for ALEC on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Alector to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,440.00 in company stock.

Percentage Held by Insiders

Only 9.10% of the stock of Alector is held by insiders.

Percentage Held by Institutions

85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALEC Stock Analysis - Frequently Asked Questions

How have ALEC shares performed this year?

Alector's stock was trading at $1.89 at the start of the year. Since then, ALEC stock has decreased by 15.9% and is now trading at $1.59.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) posted its earnings results on Wednesday, February, 26th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.59. The firm had revenue of $54.24 million for the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative trailing twelve-month return on equity of 100.58% and a negative net margin of 139.74%.
Read the conference call transcript.

Does Alector have any subsidiaries?

Alector subsidiaries include these companies: Alector LLC.

When did Alector IPO?

Alector (ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 2/26/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALEC
• CIK: 1653087
• Web: www.alector.com
• Phone: (415) 231-5660
• Fax: N/A
• Employees: 270
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Alector: $4.00
• High Price Target: $10.00
• Low Price Target: $1.00
• Potential Upside/Downside: +151.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.05 million
• Net Margins: -139.74%
• Pretax Margin: -139.60%
• Return on Equity: -100.58%
• Return on Assets: -25.15%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 3.34
• Quick Ratio: 3.34

Sales & Book Value

• Annual Sales: $100.56 million
• Price / Sales: 1.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 99,990,000
• Free Float: 90,894,000
• Market Cap: $158.98 million
• Optionable: Optionable
• Beta: 0.74